Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Anktiva

(ank-TEE-vuh)
A drug used with bacillus Calmette-Guérin (BCG) to treat adults with bladder cancer that has not invaded the muscle layers of the bladder and with carcinoma in situ. Patients may or may not have a papillary tumor (a tumor that looks like long, thin “finger-like” growths). Anktiva is used in patients whose cancer has not gotten better after treatment with BCG. It is given with BCG as a solution through a catheter (thin tube) that is placed into the bladder. It is also being studied in the treatment of other types of cancer. Anktiva binds to receptors for the protein interleukin-15 (IL-15), which is found on certain types of immune cells. This may help the immune cells kill cancer cells better than BCG alone. Anktiva is a type of IL-15 receptor agonist and a type of immunotherapy. Also called nogapendekin alfa inbakicept.
More Information
Search NCI's Dictionary of Cancer Terms